Table 3.
Risk of Hip, Clinical Vertebral, Wrist, and All Clinical Fractures Comparing High Versus Lower Compliance With Placebo and Alendronate
| Placebo | Alendronate | |||
|---|---|---|---|---|
| Fracture type | Lower compliance | High compliance | Lower compliance | High compliance |
| Hip, n | 8 | 38 | 10 | 20 |
| Crude ratea | 5.0 | 3.6 | 6.3 | 1.9 |
| Crude HR | 1.0 (referent) | 0.67 (0.3–1.45) | 1.0 (referent) | 0.30 (0.14–0.63) |
| Adjustedb HR | 1.0 (referent) | 0.67 (0.30–1.45) | 1.0 (referent) | 0.46 (0.19–1.10) |
| Clinical vertebral, n | 10 | 67 | 11 | 31 |
| Crude ratea | 6.3 | 6.4 | 6.9 | 2.9 |
| Crude HR | 1.0 (referent) | 0.99 (0.51–1.94) | 1.0 (referent) | 0.43 (0.22–0.87) |
| Adjustedb HR | 1.0 (referent) | 1.05 (0.53–2.06) | 1.0 (referent) | 0.51 (0.24–1.09) |
| Wrist, n | 11 | 99 | 14 | 91 |
| Crude ratea | 7.0 | 9.5 | 8.6 | 8.7 |
| Crude HR | 1.0 (referent) | 1.34 (0.72–2.50) | 1.0 (referent) | 0.94 (0.53–1.65) |
| Adjustedb HR | 1.0 (referent) | 1.18 (0.63–2.23) | 1.0 (referent) | 1.05 (0.57–1.93) |
| Any clinical fracture, n | 57 | 435 | 64 | 349 |
| Crude ratea | 39.0 | 44.5 | 43.2 | 35.1 |
| Crude HR | 1.0 (referent) | 1.11 (0.84–1.47) | 1.0 (referent) | 0.80 (0.61–1.04) |
| Adjustedb HR | 1.0 (referent) | 1.06 (0.80–1.41) | 1.0 (referent) | 0.87 (0.65–1.15) |
HR = hazard ratio.
a
Per 1000 person-years.
b
Adjusted for age, baseline BMD, height, BMI, self-reported health, smoking status, dietary calcium intake, calcium/vitamin D supplement provided by study, having a broken bone after age 45, and having a vertebral fracture at baseline.